BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 20089371)

  • 21. Multifactorial approach to predicting resistance to anthracyclines.
    Desmedt C; Di Leo A; de Azambuja E; Larsimont D; Haibe-Kains B; Selleslags J; Delaloge S; Duhem C; Kains JP; Carly B; Maerevoet M; Vindevoghel A; Rouas G; Lallemand F; Durbecq V; Cardoso F; Salgado R; Rovere R; Bontempi G; Michiels S; Buyse M; Nogaret JM; Qi Y; Symmans F; Pusztai L; D'Hondt V; Piccart-Gebhart M; Sotiriou C
    J Clin Oncol; 2011 Apr; 29(12):1578-86. PubMed ID: 21422418
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Amplification and overexpression of topoisomerase IIalpha predict response to anthracycline-based therapy in locally advanced breast cancer.
    Coon JS; Marcus E; Gupta-Burt S; Seelig S; Jacobson K; Chen S; Renta V; Fronda G; Preisler HD
    Clin Cancer Res; 2002 Apr; 8(4):1061-7. PubMed ID: 11948114
    [TBL] [Abstract][Full Text] [Related]  

  • 23. HER-2 amplification and topoisomerase IIalpha gene aberrations as predictive markers in node-positive breast cancer patients randomly treated either with an anthracycline-based therapy or with cyclophosphamide, methotrexate, and 5-fluorouracil.
    Di Leo A; Gancberg D; Larsimont D; Tanner M; Jarvinen T; Rouas G; Dolci S; Leroy JY; Paesmans M; Isola J; Piccart MJ
    Clin Cancer Res; 2002 May; 8(5):1107-16. PubMed ID: 12006526
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Topoisomerase II alpha as a marker predicting anthracyclines' activity in early breast cancer patients: ready for the primetime?
    Di Leo A; Biganzoli L; Claudino W; Licitra S; Pestrin M; Larsimont D
    Eur J Cancer; 2008 Dec; 44(18):2791-8. PubMed ID: 18993056
    [TBL] [Abstract][Full Text] [Related]  

  • 25. HER-2 and topoisomerase II as predictors of response to chemotherapy.
    Pritchard KI; Messersmith H; Elavathil L; Trudeau M; O'Malley F; Dhesy-Thind B
    J Clin Oncol; 2008 Feb; 26(5):736-44. PubMed ID: 18258981
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evaluation of HER-2/neu amplification and other biological markers as predictors of response to neoadjuvant anthracycline-based chemotherapy in primary breast cancer: the role of anthracycline dose intensity.
    Bozzetti C; Musolino A; Camisa R; Bisagni G; Flora M; Bassano C; Martella E; Lagrasta C; Nizzoli R; Personeni N; Leonardi F; Cocconi G; Ardizzoni A
    Am J Clin Oncol; 2006 Apr; 29(2):171-7. PubMed ID: 16601438
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Underpinning the repurposing of anthracyclines towards colorectal cancer: assessment of topoisomerase II alpha gene copy number alterations in colorectal cancer.
    Nygård SB; Christensen IJ; Smith DH; Nielsen SL; Jensen NF; Nielsen HJ; Vainer B; Brünner N
    Scand J Gastroenterol; 2013 Dec; 48(12):1436-43. PubMed ID: 24138107
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Topoisomerase IIalpha and APE/ref-1 are associated with pathologic response to primary anthracycline-based chemotherapy for breast cancer.
    Minisini AM; Di Loreto C; Mansutti M; Artico D; Pizzolitto S; Piga A; Puglisi F
    Cancer Lett; 2005 Jun; 224(1):133-9. PubMed ID: 15911109
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Changes of topoisomerase IIalpha expression in breast tumors after neoadjuvant chemotherapy predicts relapse-free survival.
    Tinari N; Lattanzio R; Natoli C; Cianchetti E; Angelucci D; Ricevuto E; Ficorella C; Marchetti P; Alberti S; Piantelli M; Iacobelli S
    Clin Cancer Res; 2006 Mar; 12(5):1501-6. PubMed ID: 16533774
    [TBL] [Abstract][Full Text] [Related]  

  • 30. HER2 expression and efficacy of preoperative paclitaxel/FAC chemotherapy in breast cancer.
    Andre F; Mazouni C; Liedtke C; Kau SW; Frye D; Green M; Gonzalez-Angulo AM; Symmans WF; Hortobagyi GN; Pusztai L
    Breast Cancer Res Treat; 2008 Mar; 108(2):183-90. PubMed ID: 17468948
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Amplification of TOP2A and HER-2 genes in breast cancers occurring in patients harbouring BRCA1 germline mutations.
    Hagen AI; Bofin AM; Ytterhus B; Maehle LO; Kjellevold KH; Myhre HO; Møller P; Lønning PE
    Acta Oncol; 2007; 46(2):199-203. PubMed ID: 17453369
    [TBL] [Abstract][Full Text] [Related]  

  • 32. HER2 and topoisomerase IIalpha: possible predictors of response to neoadjuvant chemotherapy for breast cancer patients.
    Zhu L; Li YF; Chen WG; He JR; Peng CH; Zhu ZG; Li HW
    Chin Med J (Engl); 2008 Oct; 121(20):1965-8. PubMed ID: 19080257
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Increased topoisomerase IIalpha expression in colorectal cancer is associated with advanced disease and chemotherapeutic resistance via inhibition of apoptosis.
    Coss A; Tosetto M; Fox EJ; Sapetto-Rebow B; Gorman S; Kennedy BN; Lloyd AT; Hyland JM; O'Donoghue DP; Sheahan K; Leahy DT; Mulcahy HE; O'Sullivan JN
    Cancer Lett; 2009 Apr; 276(2):228-38. PubMed ID: 19111388
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Low-level TOP2A amplification in prostate cancer is associated with HER2 duplication, androgen resistance, and decreased survival.
    Murphy AJ; Hughes CA; Barrett C; Magee H; Loftus B; O'Leary JJ; Sheils O
    Cancer Res; 2007 Mar; 67(6):2893-8. PubMed ID: 17363613
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Topoisomerase 2A gene amplification in breast cancer. Critical evaluation of different FISH probes.
    Varga Z; Moelans CB; Zuerrer-Hardi U; Ramach C; Behnke S; Kristiansen G; Moch H
    Breast Cancer Res Treat; 2012 Jun; 133(3):929-35. PubMed ID: 22083232
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical evaluation of developed PCR-based method with hydrolysis probes for TOP2A copy number evaluation in breast cancer samples.
    Zaczek A; Markiewicz A; Jaśkiewicz J; Pieńkowski T; Rhone P; Jassem J; Wełnicka-Jaśkiewicz M
    Clin Biochem; 2010 Jul; 43(10-11):891-8. PubMed ID: 20441774
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Gene expression profiles of breast cancer obtained from core cut biopsies before neoadjuvant docetaxel, adriamycin, and cyclophoshamide chemotherapy correlate with routine prognostic markers and could be used to identify predictive signatures.
    Rody A; Karn T; Gätje R; Kourtis K; Minckwitz G; Loibl S; Munnes M; Ruckhäberle E; Holtrich U; Kaufmann M; Ahr A
    Zentralbl Gynakol; 2006 Apr; 128(2):76-81. PubMed ID: 16673249
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Topoisomerase II-alfa gene as a predictive marker of response to anthracyclines in breast cancer.
    Almeida D; Gerhard R; Leitão D; Davilla C; Damasceno M; Schmitt F
    Pathol Res Pract; 2014 Oct; 210(10):675-9. PubMed ID: 25042383
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Topoisomerase 2 alpha and the case for individualized breast cancer therapy.
    Glynn RW; Miller N; Whelan MC; Kerin MJ
    Ann Surg Oncol; 2010 May; 17(5):1392-7. PubMed ID: 20217261
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Correlation of BRCA1 and APC aberrant methylation with the response to anthracycline-based neoadjuvant chemotherapy in primary breast cancer].
    Yuan P; Xu Y; Ouyang T; Wang TF; Fan ZQ; Fan T; Lin BY; Xie YT; Li JF
    Zhonghua Zhong Liu Za Zhi; 2009 Apr; 31(4):282-6. PubMed ID: 19615284
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.